GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

The new multi-purpose facility will be able to produce sterile liquid vaccines and medicines and will also include an R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK intends to establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. The planned expansion will double the size and capacity of the Marietta site.

Regis Simard, president Global Supply Chain, GSK, said: This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next-generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.”

Construction of the new facilities is expected to start by the end of this year. According to GSK, the drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.

© GSK
© GSK

Company

Logo:

GlaxoSmithKline (GSK) plc

980 Great West Road
Brentford, TW8 9GS
UK

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.